Here’s a recap of the “Novel Initiatives to Address Disparities in Cancer” session presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
Addressing Disparities in Cancer: Novel Initiatives from ASCO 2021
Led by Dr. Miguel Angel Villalona-Calero from the City of Hope Comprehensive Cancer Center, the session titled “Novel Initiatives to Address Disparities in Cancer” at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting featured six presentations focusing on the racial disparities that are often seen in cancer care and clinical trials as well as the opioid epidemic.
Here’s a recap of those presentations.
Accrual of Black Participants to Cancer Clinical Trials Following a 5-Year Prospective Initiative of Community Outreach & Engagement
Director of the Abramson Cancer Center (ACC) at Penn Medicine Dr. Robert Vonderheide shared the center’s recent initiative to address the lack of inclusion in clinical trials.
On a national level, Black participants only comprise 5 percent of cancer clinical trial enrollments. This disparity is especially jarring considering that there’s higher incidence and rates of cancer mortality among Black patients.
To help address this gap, the ACC organized a dual approach comprised of community outreach and enrollment initiatives. Some of the community-based strategy goals included:
- Build trust among Black patients
- Establish bi-directional relationships
- Produce culturally tailored marketing strategies
- Mitigate transportation barriers
- Address the needs of non-English speakers
Notable results from the above strategies included the organization of 45 patient-specific conferences on cancer education, more than 120 roundtrips to the ACC were provided via a partnership with Ride Health, more than 1,000 patients engaged with the colorectal screening navigation program, and more than 4,000 patients engaged in the breast cancer screening navigation program.
Despite limitations like the fact that the ACC only focused on the Philadelphia area, Dr. Vonderheide believes that multifaceted community and center-based engagement initiatives can encourage clinical trial enrollment and resolve gaps in access to care.
Effect of an Antiracism Intervention on Disparities in Time to Lung Cancer Surgery
Although racial disparities in lung cancer surgery have been well described and persistent for more than 20 years, very little has been done to address them.
That’s why Dr. Jacob N. Stein and his team from the UNC Lineberger Comprehensive Cancer Center organized the Accountability for Cancer Care Through Undoing Racism and Equity (ACCURE) intervention.
Developed through a community-academic partnership, ACCURE was tested in a pragmatic trial and comparison arms to determine the intervention’s ability to reduce time to surgery through the following strategies:
- Real-time transparency to help identify patients missing key milestones in care
- Patient-centered communication in which nurses and physicians connected with patients and clinical teams to resolve barriers
- Race-specific accountability to inform clinical teams which patients were receiving care
Through the above strategies, Dr. Stein found that ACCURE eliminated time-to-treatment disparities in that the rates of surgery within 8 weeks improved for both Black and white patients with early-stage lung cancer, proving that there are ways to improve equity in timely lung cancer care. This is especially important since delays in treatment are associated with disease progression, upstaging, and worse survival.
Effective Approaches to Reducing Disparities in Cancer Care & Clinical Trials
Joining the session to help drive the importance of Drs. Vonderheide and Stein’s work was medical oncologist Dr. Christopher Lathan from the Dana Farber Cancer Institute. Dr. Lathan began by summarizing the three key themes from the first two presentations:
- Community-facing navigation as a central tool in healthcare delivery implementation
- Bi-directional community involvement
- Data collection and integration
Dr. Lathan acknowledged that while cancer diagnosis and treatment is complex, patients with the most disease burden tend to have the most restrictions, which makes equitable cancer care access and inclusive clinical trials all the more important.
He then concluded by emphasizing that oncologists need to hold their institutions accountable by supporting the implementation of interventions—like the one ACC organized and ACCURE—that turn words into actions that have impact.
Impact of the VA Opioid Safety Initiative on Pain Management for Cancer Patients
Switching gears from racial disparities to the opioid epidemic, resident physician in the Department of Radiation Oncology at Stanford University Dr. Mallika Marar discussed her recent study that was developed in response to policies that have been implemented to curb high-risk opioid prescribing, such as the Veteran’s Health Administration (VHA) Opioid Safety Initiative (OSI).
To find out the impact of the OSI on opioid prescribing patterns and opioid-related toxicity among patients undergoing cancer treatment, this study examined 42,064 opioid-naïve patients with cancer who were treated at the VHA between January 2011 and December 2016.
Below is an overview of the results based on the primary and secondary outcomes:
- New opioid prescriptions increased on a monthly basis pre-OSI and decreased on a monthly basis post OSI
- High-dose opioid prescriptions were rare, and the monthly rate remained stable pre- and post-OSI
- Concomitant benzodiazepine prescriptions were stable pre-OSI and decreased post-OSI
These results show that the OSI implementation was associated with a decreasing incidence of new and persistent opioid prescriptions. It was also associated with an increase in pain-related ED visits, but according to Dr. Marar, more research is needed on patient-centered outcomes.
Less Is More: Postoperative Pain Management Using Restrictive Opioid Protocols in All Surgical Services in a Comprehensive Cancer Center
New and persistent opioid use has been noted following most surgical procedures, and the risk of chronic use has been shown to be higher based on the duration of the initial prescription. But Dr. Jason Riccuiti from the Department of Gynecologic Oncology at Roswell Park Comprehensive Cancer Center believed there was an opportunity for change.
So he and his team designed a study that aimed to demonstrate that postsurgical acute pain can be effectively managed across different surgical specialties with a reduced number of opioids.
As part of a restrictive opioid prescribing protocol (ROPP), provider-directed interventions were implemented, including modifications to the EHR interface, pharmacy review before discharge, and performance insights compared to other peers, along with patient-directed interventions, such as pre-op counseling, educational videos, and post-op surveys.
As a result of these physician- and patient-directed interventions, Dr. Riccuiti found:
- A 45 percent reduction in post-op opioid prescriptions
- Patients had fewer refill requests
- Patients were satisfied with their post-op pain control
Based on the above findings, Dr. Riccuiti concluded by saying that the implementation of protocols like ROPP are possible and that they result in significant decreases in prescribed opioids without impacting patient outcomes.
The Opioid Epidemic: Tailoring Narcotic Availability for Patients with Cancer
Rounding out the session was Dr. Chad Brummett, who’s one of the Co-Directors of the Opioid Prescribing Engagement Network (OPEN) at the University of Michigan. To help explain why this focus on the opioid epidemic is so important for oncologists, Dr. Brummett quoted the statistic that 19 percent of breast cancer patients undergoing curative surgery become new or persistent opioid users, which is a trend seen across other types of cancers as well.
And while Dr. Brummett can understand why surgeons tend to prescribe so much as they’re concerned about refill rates and patient satisfaction, he turned to the results from the previous sessions given by Drs. Marar and Riccuiti, which showed that the amount of opioids prescribed after surgery did not have any impact on patient satisfaction or refill rates.
To conclude, Dr. Brummet provided the following practical guidelines for post-op prescribing:
- Educate patients and set expectations
- Encourage non-opioid treatments
- Avoid co-prescribing
- Check PDMP before prescribing opioids
Regardless of whether a presenter was speaking on racial disparities or the opioid epidemic, a common theme throughout the “Novel Initiatives to Address Disparities in Cancer” session was the importance of keeping in mind the person behind the patient at all times.
What insights and initiatives from the 2021 ASCO annual meeting can help us address racial disparities in cancer care and the opioid epidemic?
- Project Oncology®
Prostate Cancer Care: Improving Hormonal Therapy Sequencing Post-Treatment Intensification
Zachery Reichert MD, PhD
- Project Oncology®
Prostate Cancer Care: Overcoming Challenges in Delivering Germline Testing to Veterans
Daniel Kwon, MD
Neal Shore, MD